MX2015015339A - Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos. - Google Patents
Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.Info
- Publication number
- MX2015015339A MX2015015339A MX2015015339A MX2015015339A MX2015015339A MX 2015015339 A MX2015015339 A MX 2015015339A MX 2015015339 A MX2015015339 A MX 2015015339A MX 2015015339 A MX2015015339 A MX 2015015339A MX 2015015339 A MX2015015339 A MX 2015015339A
- Authority
- MX
- Mexico
- Prior art keywords
- glucagon receptor
- methods
- glucose
- receptor antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente invención proporciona anticuerpos antagonizantes que se enlazan al receptor de glucagón y métodos para el uso de los mismos. Los anticuerpos de receptor anti-glucagón pueden ser usados terapéuticamente para reducir los niveles de glucosa en la sangre, y se pueden usar en la prevención y/o tratamiento de padecimientos relacionados con la glucosa, que incluyen diabetes, hiperglucemia, hiperinsulinemia, glucosa en ayunas deteriorada, tolerancia deteriorada a la glucosa, dislipidemia, o síndrome metabólico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361820604P | 2013-05-07 | 2013-05-07 | |
US201461981115P | 2014-04-17 | 2014-04-17 | |
PCT/IB2014/061166 WO2014181229A2 (en) | 2013-05-07 | 2014-05-02 | Anti-glucagon receptor antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015339A true MX2015015339A (es) | 2016-07-15 |
Family
ID=50884431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015339A MX2015015339A (es) | 2013-05-07 | 2014-05-02 | Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9248189B2 (es) |
EP (1) | EP2994489A2 (es) |
JP (1) | JP2016520058A (es) |
KR (1) | KR20160005749A (es) |
CN (1) | CN105189560A (es) |
AU (1) | AU2014264295A1 (es) |
CA (1) | CA2911412A1 (es) |
HK (1) | HK1218421A1 (es) |
MX (1) | MX2015015339A (es) |
PE (1) | PE20151871A1 (es) |
PH (1) | PH12015502547A1 (es) |
RU (1) | RU2015147721A (es) |
SG (1) | SG11201508264UA (es) |
TW (2) | TW201446803A (es) |
WO (1) | WO2014181229A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10610504B2 (en) * | 2014-12-23 | 2020-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Alpha-cell re-generation combined with conversion to beta cells |
MX2017012694A (es) * | 2015-04-02 | 2018-03-07 | Remb Biotherapeutics Inc | Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon. |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
US20190062441A1 (en) * | 2015-10-07 | 2019-02-28 | Remd Biotherapeutics, Inc. | Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies |
US20190002577A1 (en) * | 2016-01-04 | 2019-01-03 | Remd Biotherapeutics, Inc. | Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies |
WO2018005445A1 (en) | 2016-06-27 | 2018-01-04 | The Broad Institute, Inc. | Compositions and methods for detecting and treating diabetes |
JP7038707B2 (ja) * | 2016-06-27 | 2022-03-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害の治療に有用な化合物 |
MA46089A (fr) | 2016-08-30 | 2019-07-10 | Regeneron Pharma | Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon |
EP3529278A1 (en) * | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
MX2019008722A (es) * | 2017-01-27 | 2019-10-02 | Ngm Biopharmaceuticals Inc | Proteínas de unión al receptor de glucagón y métodos para usarlas. |
CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
WO2020023847A1 (en) | 2018-07-27 | 2020-01-30 | Ngm Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
MX2021007444A (es) | 2018-12-21 | 2021-08-05 | Jiangsu Hengrui Medicine Co | Proteina biespecifica. |
CN110898225A (zh) * | 2019-12-23 | 2020-03-24 | 黑龙江中医药大学 | mTOR/S6K1及MAPK信号通路抑制在胰岛素抵抗改善中的应用 |
CN113045657B (zh) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | 一种人源化抗人bcma单克隆抗体及其car-t细胞 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
WO1994005789A1 (en) | 1992-08-28 | 1994-03-17 | Zymogenetics, Inc. | Glucagon receptors |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
DE69435233D1 (de) | 1993-09-15 | 2009-10-08 | Novartis Vaccines & Diagnostic | Rekombinante Alphavirus Vektoren |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
ATE437232T1 (de) | 1993-10-25 | 2009-08-15 | Canji Inc | Rekombinanter adenoviren-vektor und verfahren zur verwendung |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
ATE381624T1 (de) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | Retrovirale vektoren mit verminderter rekombinationsrate |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
PE20091674A1 (es) * | 2008-03-27 | 2009-11-04 | Lilly Co Eli | Antagonistas del receptor de glucagon |
CA2772590C (en) * | 2009-09-08 | 2017-01-03 | Neopharm Co., Ltd. | Antibodies against glucagon receptor and their use |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
-
2014
- 2014-05-02 KR KR1020157034642A patent/KR20160005749A/ko not_active Application Discontinuation
- 2014-05-02 PE PE2015002374A patent/PE20151871A1/es not_active Application Discontinuation
- 2014-05-02 EP EP14727928.5A patent/EP2994489A2/en not_active Withdrawn
- 2014-05-02 CA CA2911412A patent/CA2911412A1/en not_active Abandoned
- 2014-05-02 SG SG11201508264UA patent/SG11201508264UA/en unknown
- 2014-05-02 CN CN201480026244.5A patent/CN105189560A/zh active Pending
- 2014-05-02 JP JP2016512455A patent/JP2016520058A/ja active Pending
- 2014-05-02 US US14/268,933 patent/US9248189B2/en not_active Expired - Fee Related
- 2014-05-02 MX MX2015015339A patent/MX2015015339A/es unknown
- 2014-05-02 RU RU2015147721A patent/RU2015147721A/ru not_active Application Discontinuation
- 2014-05-02 WO PCT/IB2014/061166 patent/WO2014181229A2/en active Application Filing
- 2014-05-02 AU AU2014264295A patent/AU2014264295A1/en not_active Abandoned
- 2014-05-06 TW TW103116190A patent/TW201446803A/zh unknown
- 2014-05-06 TW TW105131941A patent/TW201702274A/zh unknown
-
2015
- 2015-11-06 PH PH12015502547A patent/PH12015502547A1/en unknown
- 2015-12-21 US US14/976,301 patent/US20160311912A1/en not_active Abandoned
-
2016
- 2016-06-03 HK HK16106367.4A patent/HK1218421A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12015502547A1 (en) | 2016-02-22 |
SG11201508264UA (en) | 2015-11-27 |
JP2016520058A (ja) | 2016-07-11 |
EP2994489A2 (en) | 2016-03-16 |
CA2911412A1 (en) | 2014-11-13 |
TW201702274A (zh) | 2017-01-16 |
TW201446803A (zh) | 2014-12-16 |
HK1218421A1 (zh) | 2017-02-17 |
RU2015147721A (ru) | 2017-06-15 |
WO2014181229A2 (en) | 2014-11-13 |
WO2014181229A3 (en) | 2015-04-16 |
US20160311912A1 (en) | 2016-10-27 |
KR20160005749A (ko) | 2016-01-15 |
AU2014264295A1 (en) | 2015-10-29 |
US20140335091A1 (en) | 2014-11-13 |
US9248189B2 (en) | 2016-02-02 |
CN105189560A (zh) | 2015-12-23 |
PE20151871A1 (es) | 2015-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502547A1 (en) | Anti-glucagon receptor antibodies and methods of use thereof | |
PH12017500402A1 (en) | Anti-glucagon antibodies and uses thereof | |
PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
MX2016015997A (es) | Preparacion y uso de beta-d-nicotinamida ribosido cristalina. | |
MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
MX2015008079A (es) | Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
MX368435B (es) | Analogos del glucagon. | |
IL244668A0 (en) | Preparations and formulations for the prevention and treatment of diabetes and obesity, and methods for their production and use in the control of glucose and calories | |
TW201613633A (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
MY176022A (en) | Acylated glucagon analogues | |
EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
EA201692477A1 (ru) | Композиции и способы применения для лечения метаболических расстройств | |
WO2014031610A8 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
EA201391764A1 (ru) | Агонисты рецептора glp-1/глюкагона длительного действия | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
EA201691374A1 (ru) | Инсулин длительного действия и его применение | |
MX2019003619A (es) | Formulaciones de bromocriptina. | |
EA201591123A1 (ru) | Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств | |
HK1255271A1 (zh) | 針對胰島素受體的抗體片段和其治療低血糖的用途 |